These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34597624)

  • 1. Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    J Pharm Sci; 2022 Feb; 111(2):517-528. PubMed ID: 34597624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole.
    Segregur D; Barker R; Mann J; Moir A; Karlsson EM; Turner DB; Arora S; Dressman J
    Eur J Pharm Sci; 2021 May; 160():105750. PubMed ID: 33581261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach.
    Komasaka T; Dressman J
    Eur J Pharm Sci; 2021 Feb; 157():105630. PubMed ID: 33122010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example.
    Petrakis O; Vertzoni M; Angelou A; Kesisoglou F; Bentz K; Goumas K; Reppas C
    J Pharm Pharmacol; 2015 Jan; 67(1):56-67. PubMed ID: 25252222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs.
    Dong Z; Li J; Wu F; Zhao P; Lee SC; Zhang L; Seo P; Zhang L
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):456-465. PubMed ID: 32633893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
    Kaur N; Narang A; Bansal AK
    Eur J Pharm Biopharm; 2018 Aug; 129():222-246. PubMed ID: 29879527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide.
    Pettarin M; Bolger MB; Chronowska M; Kostewicz ES
    Eur J Pharm Sci; 2020 Dec; 155():105552. PubMed ID: 32937212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
    Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
    AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2019 Jan; 108(1):584-591. PubMed ID: 30423339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.